Document:

Exhibit 10.23

 

KSTC-184-512-07-029

 

Kentucky Science and Technology Corporation (KSTC)

 

 

Grant Agreement No. KSTC-184-512-07-029

 

Kentucky Cabinet for Economic Development

Department of Commercialization and Innovation

Kentucky SBIR-STTR Matching Funds Program

 

	
PROJECT TITLE:
    	
Cannabidiol for Transdermal Delivery
    
	
APPLICATION #:
    	
KSTC-02-DCIS-029
    
	
CONTACT PERSON:
    	
Audra Stinchcomb
    
	
GRANTEE ORGANIZATION:
    	
AllTranz, Inc.
    
	
PERFORMANCE PERIOD:
    	
1 Dec 2007-31 May 2009
    

 

GRANTOR CONTACTS

 

	
KSTC Technical Representative
    	
KSTC Administrative Representative
    
	
Kenneth D. Ronald, Program Manager
    	
John Wehrle, Chief Financial Officer
    
	
Kentucky Science and Technology Corporation
    	
Kentucky Science and Technology Corporation
    
	
P.O. Box 1049
    	
P.O. Box 1049
    
	
Lexington, KY 40588-1049
    	
Lexington, KY 40588-1049
    
	
PH: 859-255-3613 ext. 252
    	
PH: 859-233-3502 ext. 224
    
	
FX: 859-259-0986
    	
FX: 859-259-0986
    
	
E-mail: kronald@kstc.com
    	
E-mail: jwehrle@kstc.com
    

 

GRANTEE CONTACTS

 

	
Contact Person/Principal Investigator (PI)
    	
Administrative Representative
    
	
Audra Stinchcomb
    	
Jean Parlanti
    
	
Principal Investigator
    	
Staff Associate
    
	
4080 Weber Way
    	
900 S Limestone Street
    
	
Lexington, KY 40514
    	
Lexington, KY 40536-0200
    
	
PH: 859-323-6192
    	
PH: 859-257-2587
    
	
E-mail: astin2@email.ukv.edu
    	
E-mail: jparlanti@alltranz.com
    

 

Total KSTC Grant Amount: Up to $ 100,000 Research 

 

Focus Area: Human Health and Development

 

 

This GRANT AGREEMENT is made and entered into as of 21 November 2007, by and between the KENTUCKY SCIENCE and TECHNOLOGY CORPORATION, a Kentucky nonprofit corporation (“KSTC”), as administrator of the Kentucky CABINET FOR ECONOMIC DEVELOPMENT (“CABINET”), DEPARTMENT OF COMMERCIALIZATION AND INNOVATION (“DCI”) Kentucky SBIR/STTR Matching Funds Program through a Personal Service Contract with the CABINET, a governmental agency of the Commonwealth of Kentucky for and on behalf of the DCI, and AllTranz, Inc., (“Grantee”).

 

In consideration of the mutual terms, provisions and covenants contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows:

 

1.0                               TERM OF AGREEMENT.  The term of this Agreement shall be for a 18 month period effective 1 December 2007, and continuing until 31 May 2009, unless terminated at an earlier date pursuant to the terms and conditions of this Grant Agreement.

 

2.0                               STATEMENT OF WORK AND DELIVERABLES.  Grantee agrees to:

 

(a)                                 Statement of Work. Use best efforts to conduct technology and business development as outlined in the attached project timeline/Gantt chart (Exhibit A) and the approved proposal #KSTC-02-DCIS-029, which is incorporated into this Grant Agreement by reference, (which together constitute the “Project”).

 

(b)                                 Deliverables.

 

(i)                                     Reports.  Prepare and submit:

 

(1)                                 Quarterly Status Reports.  Summarize the status of Grantee’s technical and business efforts and financial progress. Use the Online Application and Reporting System to submit Quarterly Status Reports. The Quarterly Report format can be found on the Online Application System Website.  Quarterly Status Reports are required throughout the term of the Grant and are used, consistent with Program Guidelines, as prerequisites for scheduled payment of grant funds.    Quarterly Status Reports shall include a Disclosure of Inventions as set forth in Section 6.0(b) of this Agreement.  Quarterly Status Reports shall be submitted in accordance with the reporting schedule provided in Section 2.0 (b) (ii) below.

 

(2)                                 Final Report. A Final Report shall be submitted via the Online Application And Reporting System within 30 days of notification of award or denial of a Federal Phase II contract or at the completion of the Grantee’s work for the Matching Funds Program Project. Failure to file a Final Report will be an incident of Default pursuant to Section 8.1 of this Agreement. The Online Final Report shall include the following:

 

(a)                                 A summary of technical and business goals and achievements including a final financial report.

(b)                                 Date of Federal Phase II Grant and Contract amount (if granted) and Agency.

(c)                                  Explanation if Phase II was awarded but Grantee declined to accept the Grant.

(d)                                 Statement of whether the Grantee plans to continue the proposed research with its own or other resources if a Federal Phase II Grant was not awarded and whether the KY SBIR/STTR Phase I Matching Funds contributed to this decision.

(e)                                  Discussion of any material affects the Kentucky SBIR/STTR Phase I Matching Funds had on your company, including job creation and receipt of additional private or government funds.

(f)                                   List of patent applications that were filed or approved since the award of the KY SBIR-STTR Phase I Matching Funds Program Grant.

(g)                                  Disclosure of Inventions as set forth in Section 6.0(b) of this Agreement, 

(h)                                 Any general comments or suggested changes for this program.

 

The Final Report technical section shall be submitted or uploaded in Microsoft Word format electronically.  The Final Report format can be found on the Online Application System Website.

 

2

 

(3)                                 Post Award Company Status Reports.  A report shall be submitted annually for five years after the final disbursement of Matching Grant Funds to certify the continuing Kentucky based status of your Company per section 4 (i)(2).  This report can be submitted electronically within 30 days of the anniversary of your final disbursement of funds.

 

(4)                                 Copies of Federal SBIR/STTR Phase I Final Report and Phase II Federal SBIR/STTR Application. A copy of the Federal SBIR/STTR Phase I Final Report and Phase II Federal SBIR/STTR Application must be submitted electronically via the Online Application and Reporting System to qualify for second disbursement of 25% of Grant award pursuant to Program Guidelines (Exhibit C, hereto incorporated by reference)

 

(ii)                                  Reporting Schedule:

 

The Grantee/Principal Investigator (“PI”) shall submit Quarterly Status Reports and the Final Report on the following schedule.

 

	
#
    	
 
    	
Report
    	
 
    	
Due Dates
    
	
1
    	
 
    	
Quarterly Status Report
    	
 
    	
1 Mar 08, 1 Jun 08, 1 Sep 08, 1 Dec 08, 1 Mar 09
    
	
2
    	
 
    	
Phase I Matching Funds Grant Final Report
    	
 
    	
31 May 09
    
	
3
    	
 
    	
Post Award Company Status Reports
    	
 
    	
Annual Submission, (for 60 months) on   anniversary date of final disbursement of Matching Funds.
    

 

(c)                                  Full Compliance.  Fully comply with all of the terms, conditions and provisions of this Grant Agreement.

 

3.0                               GRANT FUNDING AND DETAILED BUDGET.

 

(a)                                 Funding Amount and Use.  Subject to the terms and conditions of this Agreement, KSTC hereby agrees to provide grant funds to Grantee for direct costs, consistent with the Program Guidelines (Exhibit C) an amount not to exceed $100,000 (One Hundred Thousand Dollars). All funds provided by KSTC shall be expended by Grantee: 1) in accordance with the budget as detailed in the above referenced SBIR proposal KSTC-02-DCIS-029 and all the terms and conditions of this Agreement and Program Guidelines (Exhibit C) and 2) in compliance with applicable law, including other statutory, regulatory, and contractual requirements as may be applicable to the receipt and expenditure of Commonwealth of Kentucky funds.  Equipment purchases are allowed under this Grant Agreement but are limited to $25,000 unless otherwise justified by the Applicant and approved by KSTC.

 

(b)                                 Disbursement of Funds.  Grantee shall use grant funds as directed by KSTC and in accordance with applicable law. KSTC shall disburse funds to Grantee in three installments. The first payment will be 50% of the Grant amount and will be paid upon of execution of the Grant Agreement and receipt of funds by KSTC from the Cabinet. The second installment will be 20% of the Grant amount and be disbursed upon submission of the Federal SBIR/STTR Phase I grant final report, and the Federal Phase II Application. The third installment will be 20% of the Grant amount and be disbursed after submission of a additional Quarterly Status Report after above payment requirements are met and verification of the final payment under the Federal Phase I contract. The final installment will be up to the remaining 10% of the Grant amount, which will be paid upon submission and acceptance of the Matching Funds Award Phase I Final Report.  The Grantee will provide KSTC the name and business account number of the bank to which it desires grant payment to be made by KSTC electronically.

 

(c)                                  Availability of Funds.  The Parties to this Agreement acknowledge that KSTC has entered into a Personal Service Contract with the Cabinet to administer the Kentucky SBIR/STTR Matching Funds Program.

 

3

 

KSTC has been approved to receive funding from the Cabinet to enable KSTC to fund the Grant to Grantee.  The Parties further acknowledge that under KSTC’s Personal Service Contract with the Cabinet both KSTC and the Cabinet have the unrestricted right to terminate their Personal Service Contract with or without cause upon thirty days written notice. The Parties agree that KSTC’s obligation to provide funding to Grantee is contingent and conditioned upon KSTC receiving funding for such purpose from the Cabinet.  The Parties further agree that KSTC shall have the unrestricted right to terminate this Agreement immediately and without notice in its sole and absolute discretion in the event the Cabinet terminates or reduces funding to KSTC or requires KSTC to repay unspent funds, or in the event that either KSTC or the Cabinet exercise their unrestricted right to terminate their Personal Service Contract with or without cause.  In such event the Parties agree that any remaining unexpended and uncommitted funds shall be returned to KSTC by the Grantee.

 

(d)                                 Binding Effect. This Agreement has been duly authorized, executed and delivered by Grantee. Simultaneously with its execution and delivery of this Agreement, Grantee shall deliver to KSTC copies, certified by an officer or other appropriate representative of Grantee, of the resolutions of the governing body of Grantee authorizing this Agreement, and the transactions described herein.

 

(e)                                  Retention of Records.The Grantee shall retain all financial records, supporting documents, statistical records, and all other records pertaining directly or indirectly to this Grant Agreement for a period of three (3) years after KSTC has accepted Grantee’s final report or as otherwise required by applicable law.

 

(f)                                   Financial Management System. Prior to receipt of grant funds, the Grantee shall have in place an overall financial management system sufficient to ensure effective control over and accountability for all funds received. Accounting records must be supported by source documentation such as time sheets and invoices. A financial status report will be included in the Status Report submitted each quarter.

 

4.0                               GENERAL TERMS, CONDITIONS AND REPRESENTATIONS.

 

(a)                                 KSTC Monitoring.  KSTC is responsible for the administration of the Kentucky SBIR/STTR Matching Funds Program and to monitor Grantee’s performance under this Grant.

 

(b)                                 Kentucky Based Company.  The Grantee has its principal office of operation in Kentucky and no less than fifty-one percent (51%) each of its property and payroll is located in Kentucky.  By signing this Agreement, the Grantee certifies that the Company is registered with and in “Good Standing” with the Kentucky Secretary of State, is current with the Kentucky Department of Revenue, and that the company qualifies as a Kentucky Based Company.

 

(c)                                  Property.  Property for the purposes of the Kentucky SBIR/STTR Matching Funds Program includes real property and other business and personal property that are subject to depreciation under the Federal Tax Code and any amendments thereto.

 

(d)                                 Payroll.  Payroll, for the purposes of the Kentucky SBIR/STTR Matching Funds Program, is the number of full-time employees working directly for the project, fifty-one percent (51%) or more of whom must be bona fide Kentucky residents; AND the gross payroll of the Grantee, fifty-one percent (51%) or more of which must be paid to bona fide Kentucky residents.

 

(e)                                  Principal Investigator.  The Grantee shall require the Principal Investigator to conduct and oversee the conduct of the work described in Section 29 and Appendix A of the Grant Application, to provide all reports required by Section 2.0 above and to perform all other duties required of the Grantee and PI by this Grant Agreement.

 

(f)                                   Termination or Resignation of Principal Investigator.  If the Grantee terminates the PI, or the PI gives Grantee notice of intent to resign from his/her position with Grantee, Grantee shall notify KSTC’s Technical Representative of such in writing within 7 (seven) days of notice or termination.  Within 15 (fifteen) days of such notification, Grantee shall notify the KSTC Technical Representative in writing of the alternate arrangements Grantee shall take to complete its obligation under this Grant Agreement.

 

4

 

(g)                                  Changes in Scope of Project.  Any material change in the scope of the Project, including PI and other identified investigators, is strictly subject to KSTC’s prior written approval.

 

(h)                                 Required Insurance Coverages.  Grantee shall maintain and upon request furnish evidence to KSTC of the insurance coverages required by law or as reasonably requested by KSTC, all in such amounts and with such carriers as are reasonable acceptable to KSTC.

 

(i)                                     Transfer to Other State.

 

(1)                                 The Kentucky SBIR/STTR Matching Grant funding under this Grant Agreement is intended for the Grantee to conduct Project related tasks as long as the Grantee maintains its Kentucky-based Company status and conducts no less than 51% of the Project work within the Commonwealth of Kentucky.  If the Grantee’s Kentucky based business status changes, a default will occur and immediate termination will result. All funds received prior to the date of the termination shall be repaid to KSTC.

 

(2)                                 The Grantee agrees to retain its Kentucky-based status, as defined in the Program Guidelines, for not less than sixty (60) months after the date of final disbursement of Grant funds.  The Grantee’s failure to meet this requirement will constitute a default by the Grantee resulting in immediate termination of the Grant Agreement, and Grantee will be required to repay one hundred percent (100%) of the Matching Fund Grant to KSTC.  Grantee shall provide a CPA certification of its Kentucky-based status within 30 days of the anniversary date of the date of final disbursement of Grant funds for five (5) years thereafter if specifically requested.  This certification may be submitted with the company post award annual status report.  The Parties agree that the requirement of this Subsection is enforceable beyond the term of the Agreement as stated in Section 1.0.

 

(j)                                    Compliance with Law.  The Grantee and the PI agree to comply with all applicable federal, state and local laws and regulations regarding civil rights, equal opportunity and affirmative action in their performance of this Grant Agreement. KSTC, DCI, the Cabinet and the Commonwealth of Kentucky assume no responsibility for oversight of Grantee’s compliance with or for Grantee’s failure in complying with any federal, state and local laws and regulations.

 

5.0                               GRANT PERFORMANCE AND REVIEWS.  The Grantee agrees to require the PI to:

 

(a)                                 Periodic Review.  Submit to periodic grant progress reviews by KSTC in accordance with applicable state regulations.

 

(b)                                 Inspections.  Upon KSTC’s request, permit representatives of KSTC to inspect and make copies of any records pertaining to matters covered by this Grant Agreement.

 

(c)                                  Meetings.  Be available for periodic management and technical review meetings as may be reasonably requested by KSTC.

 

6.0                               INTELLECTUAL PROPERTY PROVISIONS.

 

(a)                                 Grantee’s Rights.  All rights and title to all inventions, improvements and/or discoveries, including software, know-how, patent and other intellectual or proprietary property, conceived and/or made by one or more employees of Grantee in the performance of this Grant Agreement shall belong to the Grantee.

 

(b)                                 Disclosure of Inventions. The Grantee agrees to provide to KSTC a list of all invention disclosures and provisional and regular patent applications, including the filing date, serial number and title, patent number and issue date, for any subject invention in any country in which the Grantee has applied for a patent. If none, a report indicating so shall be provided.

 

5

 

7.0                               ACKNOWLEDGEMENT.

 

(a)                                 Patents.  The Grantee agrees to include, within the specification of any United States patent application and any patent issuing thereon covering a subject invention, the following statement: “This invention was made with an award from the Kentucky Cabinet for Economic Development, Department of Commercialization and Innovation, under Grant Agreement KSTC-184-512-07-029 with the Kentucky Science and Technology Corporation.”

 

(b)                                 Publications and Reports.  Grantee and all its PIs shall acknowledge the Grant received from KSTC in all publications (peer reviewed or non-peer reviewed) and presentations arising out of the work conducted under this Grant Agreement.  The acknowledgement of the Grant shall also be made in all internal and external reports or other reports of any kind. A copy of each such publication or report shall be provided to the KSTC Technical Representative. The acknowledgement shall state: “This technology was supported in part by an award from the Kentucky Cabinet for Economic Development, Department of Commercialization and Innovation, under the Grant Agreement KSTC-184-512-07-029 with the Kentucky Science and Technology Corporation.”

 

8.0                               EVENTS OF DEFAULT.

 

8.1                               Each of the following shall constitute an Event of Default under this Grant Agreement:

 

(a)                                 Unsatisfactory Progress.  If KSTC, in its sole and absolute discretion, determines that Grantee or PI has failed to make satisfactory progress in conducting the work of the Project or otherwise is not in compliance with the requirements and provisions of this Grant Agreement, KSTC may terminate this Grant Agreement immediately upon written notice to Grantee.  Any remaining unexpended and uncommitted funds shall be returned to KSTC.

 

(b)                                 Bankruptcy, Insolvency of a Business Grantee.  If a Grantee: (1) becomes insolvent or generally fails to pay, or admits in writing its inability to pay, debts as they become due; (2) applies for, consents to, or acquiesces in the appointment of a trustee, receiver, or other custodian for Grantee or any of Grantee’s property; (3) makes a general assignment for the benefit of creditors or in the absence of such application, consent, or acquiescence, a trustee, receiver, or other custodian is appointed for Grantee or for a substantial part of the property of Grantee and is not discharged within thirty (30) days; (4) enters into any bankruptcy, reorganization, debt arrangement, or other case or proceeding under any bankruptcy or insolvency law or any dissolution or liquidation proceeding is commenced in respect to Grantee, and if such case or proceeding is not commenced by Grantee, it is consented to or acquiesced in by Grantee or remains for thirty (30) days undismissed; or (5) takes any action to authorize, or in furtherance of, any of the foregoing.

 

(c)                                  Representations and Warranties.  If any representation or warranty made by Grantee in this Agreement is untrue, false or misleading in any material respect, or any schedule, certificate, financial statement, report, notice, or other writing furnished by Grantee to KSTC is false or misleading in any material respect.

 

(d)                                 Death or Incapacity of PI.  The death or inability of the PI to perform the work of the Project or to comply with the requirements of this Grant Agreement as a result of sickness or other incapacity of any kind, unless Grantee has complied with the provisions of Subsection 4.(f) above.

 

(e)                                  Kentucky-based Business.  The Grantee fails to remain a Kentucky-based business or to file Kentucky-based certifications as required by Subsections 4.0 (b) and 4.0 (i)(2).

 

8.2                               Remedies of KSTC upon Events of Default.  Upon the occurrence of an Event of Default, KSTC, in its sole and absolute discretion, may at any time exercise any one or more of the following rights and remedies (in addition to any other rights or remedies available under this Agreement or applicable law)

 

(a)                                 Termination.  KSTC may immediately terminate this Agreement at any time upon written notice to the Grantee. In the event of termination by KSTC, any remaining unexpended and uncommitted funds shall be returned to KSTC by Grantee; and/or

 

6

 

(b)                                 Action at Law.  Commence an appropriate legal or equitable action to enforce the Grantee’s performance of the terms, covenants and conditions of this Grant Agreement; and/or

 

(c)                                  Other Remedies.  KSTC may exercise any other rights or remedies that may be available pursuant to this Grant Agreement or under applicable law.

 

8.3                               Remedies Cumulative.  All of KSTC’s rights and remedies under this Agreement or applicable law shall be cumulative to the greatest allowable extent.

 

9.0                               TERMINATION.  Either Party may terminate this Grant Agreement at any time for cause or may terminate without cause upon thirty (30) days written notice to the other Party. In the event of termination, the Grantee shall immediately return to KSTC all unexpended and uncommitted funds received under this Grant Agreement.

 

10.0                        OTHER PROVISIONS.

 

(a)                                 Relationship of Parties.  Nothing in this Agreement shall be deemed to create a partnership or joint venture between KSTC, DCI, or Cabinet, and Grantee nor shall KSTC, DCI, or Cabinet be deemed to have made an investment in or a loan to Grantee. Further, nothing in this Grant Agreement shall make either Party, DCI, or the Cabinet, responsible for the debts or obligations of the other or create any relationship between the Parties, DCI or the Cabinet, other than as expressly set forth herein.

 

(b)                                 Indemnification.  Grantee shall indemnify, defend and hold KSTC,  DCI,  and the Cabinet harmless from and against any and all loss, cost, damage, and expense, including attorney’s fees, incurred in connection with this Grantee’s performance under this Grant Agreement or the operations of the Grantee, including but not limited to all loss as a result of bodily injury, property damage, invasion of privacy or infringement of patents, copyrights or other intellectual property rights.

 

(c)                                  Authority/No Conflict.  The execution, delivery and performance of this Grant Agreement have been duly authorized by all necessary action, have received all necessary governmental consents or approvals, if any are required, and do not and will not contravene or conflict with any provision of applicable law, the governing documents of Grantee, or any agreement or instrument binding upon Grantee or its properties.

 

(d)                                 Validity and Binding Nature.  This Agreement is valid, legal and binding obligations of the Grantee, and enforceable against the Grantee in accordance with its respective terms.

 

(e)                                  Execution of Agreements.  Grantee agrees, upon KSTC’s request, to execute any additional agreements,  documents or other papers of any kind that are convenient or necessary for the implementation of this Agreement.

 

(f)                                   Waiver; Amendments.  No delay on the part of KSTC in the exercise of any right, power, or remedy shall operate as a waiver thereof, nor shall any single or partial exercise by KSTC of any right, power, or remedy preclude other or further exercise thereof or the exercise of any other right, power, or remedy. No amendment or modification of this Agreement shall be effective unless it is in writing and signed by KSTC and Grantee. No waiver of, or consent of KSTC with respect to, any provision of this Agreement shall in any event be effective unless it is in writing and signed and delivered by KSTC, and then any such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

(g)                                  Disclosure.  (1) This agreement does not contain any false or misleading statements of or omissions of any material fact known to the Grantee that materially and adversely affects, or in the future could materially and adversely affect, the business, operations, affairs, or condition, financial or otherwise, of the Grantee that has not been disclosed to KSTC. (2) Grantee warrants that the Grantee is not aware of any actual, potential or perceived conflicts of interest which could conflict in any manner or degree with the performance of this contract. (3) No person having any such conflict of interest shall be employed by Grantee. (4) Grantee shall

 

7

 

immediately disclose to KSTC any personal and/or professional or contractual relationships which may cause, or involve, an actual, potential, or perceived conflict of interest.

 

(h)                                 Notices. All notices, requests, demands, waivers, and other communications given as provided in this Agreement shall be in writing, and shall be addressed as follows:

 

IF TO KSTC:

 

Legal Notices:                                                                   Kentucky Science and Technology Corporation
 P.O. Box 1049
 Lexington, KY 40588-1049
 Attn: Kris Kimel, President

 

Programmatic Issues:                           Kentucky Science and Technology Corporation
 P.O. Box 1049
 Lexington, KY 40588-1049
 Attn: Kenneth Ronald, Program Manager
 Via email: kronald@kstc.com

 

IF TO THE GRANTEE:

 

Legal Notices:                                                                   AIITranz, Inc.
 4080 Weber Way
 Lexington, KY 40514
 (859) 323-6192
 Attn: Audra Stinchcomb

 

Technical Notices:                                            AIITranz, Inc.
 4080 Weber Way
 Lexington, KY 40514
 (859) 323-6192
 Attn: Audra Stinchcomb

 

Unless otherwise specifically provided in this Agreement, notice hereunder shall be deemed to have been given upon its being deposited in the U.S. Mail, postage prepaid, and addressed as provided above. The Parties hereto may change their respective addresses as provided above by giving written notice of the change to the other Parties hereto as provided in this paragraph.

 

(i)                                     Costs and Expenses.  Each of the Parties shall bear and be responsible for their respective costs and expenses incurred in connection with the review and preparation of this Grant Agreement and the consummation of the transactions contemplated hereby.

 

(j)                                    Captions.  Paragraph captions used in this Agreement are for convenient reference only, and shall not affect the interpretation of this Agreement.

 

(k)                                 Governing Law.  This Grant Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Kentucky. All obligations of Grantee and rights of KSTC expressed herein shall be in addition to, and not in limitation of, those provided by applicable law.

 

(l)                                     Binding Effect.  This Grant Agreement shall be binding upon and shall inure to the benefit of KSTC and Grantee and their respective legal representatives, successors, and assigns.

 

(m)                             No Third Party Beneficiaries.  Nothing in this Grant Agreement, expressed or implied, is intended to confer any rights upon any person or entity of any kind other than KSTC and Grantee.

 

8

 

(n)                                 Survival of Warranties.  All agreements and representations made by Grantee herein shall survive the execution and delivery of this Grant Agreement and the making of the Grant.

 

(o)                                 Severability.  If any provision in this Grant Agreement shall be invalid, illegal, or unenforceable in any jurisdiction, the validity, legality, and enforceability of the remaining provisions, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

 

(p)                                 Counterparts.  This Grant Agreement and any amendments, waivers, consents, or supplements may be executed in any number of counterparts and by a different Party in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same agreement. This Grant Agreement shall become effective upon the execution of a counterpart by each of the Parties.

 

(q)                                 Further Assurances.  In addition to the acts recited in this Grant Agreement to be performed by the Parties, the Parties shall perform or cause to be performed any and all such further acts as may be reasonably necessary to consummate the transactions contemplated hereby.

 

(r)                                    Time of the Essence.  Time shall be of the essence with respect to the performance by the Parties of their obligations under this Grant Agreement.

 

(s)                                   Entire Agreement.  This Grant Agreement, including all Exhibits attached and referenced hereto, constitute the entire understanding and agreement of the Parties relative to the subject matter hereof, superseding all previous oral or written understandings and agreements relative to the subject matter hereof.

 

(t)                                    Construction.  In the construction of this Grant Agreement, the rule of construction that a document is to be construed most strictly against a Party who prepared the same shall not be applied, it being agreed that all Parties have participated in the preparation of the final form of this Grant Agreement.

 

(u)                                 Assignment.  Neither Party shall have the right to assign or otherwise transfer, in whole or in part, its rights or obligations under this Agreement, except with the prior written consent of the other Party.

 

(v)                                 Amendments.  The Grant Agreement may be amended only by the written agreement of the Parties hereto. No waiver of any of the provisions of this Grant Agreement shall be valid unless said waiver shall be in writing and signed by the Party against who said waiver is sought to be enforced.

 

(x)                                 Voluntary Act. EACH OF THE PARTIES ACKNOWLEDGES THAT THEY HAVE THOROUGHLY REVIEWED THIS GRANT AGREEMENT AND ARE ENTERING INTO THE TRANSACTIONS CONTEMPLATED HEREIN AS THEIR FREE AND VOLUNTARY ACT AND NOT IN RELIANCE UPON ANY REPRESENTATION BY THE OTHER PARTY OTHER THAN THOSE SET FORTH HEREIN. GRANTEE ACKNOWLEDGES THAT IT HAS HAD THE OPPORTUNITY TO CONSULT WITH LEGAL AND TAX COUNSEL OF ITS CHOICE REGARDING THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREIN, AND KSTC HAS ENCOURAGED GRANTEE TO CONSULT LEGAL AND TAX COUNSEL WITH RESPECT HERETO AND TO ASK ANY QUESTIONS AND RECEIVE SATISFACTORY ANSWERS REGARDING THE OBLIGATIONS CONTAINED HEREIN.

 

9

 

IN WITNESS WHEREOF, the Parties hereto have caused their authorized officials to execute this Grant Agreement as the date set forth below.

 

KENTUCKY SCIENCE AND TECHNOLOGY CORPORATION

 

	
BY: 
    	
/s/ Mahendra K.   Jain
    	
 
    	
11/21/07
    	
 
    
	
 
    	
Mahendra K. Jain,   Vice President, KSTC
    	
 
    	
Date
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
BY: 
    	
/s/ Kris W. Kimel
    	
 
    	
11/21/2007
    	
 
    
	
 
    	
Kris W. Kimel,   President, KSTC
    	
 
    	
Date
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
ALLTRANZ, INC
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
BY: 
    	
/s/ Audra   Stinchcomb
    	
 
    	
11/30/07
    	
 
    
	
 
    	
Audra Stinchcomb
    	
 
    	
Date
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
TITLE: 
    	
Principal   Investigator
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
BY: 
    	
/s/ Jean Parlanti
    	
 
    	
11/30/07
    	
 
    
	
 
    	
 
    	
 
    	
Date
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
TITLE: 
    	
Administrative POC
    	
 
    	
 
    	
 
    
	
 
    	
Jean Parlanti
    	
 
    	
 
    	
 
    

 

10

 

Exhibit H KSTC-184-512-07-029

 

11

 

The guidelines are published in its entirety online and can be found at
 http://www.kintera.org/atf/cf/%7B4A887362-9129-4A13-9200-7A21527E3A5A%7D/REVISED SOLICITATION NOTICE FINAL.pdf\

 

Exhibit B - Program Guidelines
 The Kentucky Small Business Innovation Research (SBIR) and Small Business Technology
 Transfer Research (STTR) Matching Funds Award Program

 

A. PROGRAM SUMMARY

 

The Kentucky SBIR/STTR Matching Funds Award Program is designed to award matching funds to Kentucky-based companies that have been granted a Federal Small Business Innovation Research Program or Small Business Technology Transfer Program (the “Federal SBIR/STTR Program”) Phase I or Phase II award for research in one or more of the five (5) research and development focus areas as defined in the Department of Commercialization and Innovation (DCI) 2002 Kentucky “Strategic Plan for the New Economy.” The five focus areas are: (1) Biosciences; (2) Environmental and Energy Technologies; (3) Human Health and Development; (4) Information Technology and Communications;^) Materials Science and Advanced Manufacturing (DCI Focus Areas).

 

A company may relocate to Kentucky in order to qualify for the Kentucky Matching Funds Award Program. To qualify as an out-of-state company, the company must submit an application which includes all available documentation, except those related to the Kentucky residency requirements, which must be submitted before any funds are disbursed. A Grant Agreement will be executed, and the Applicant will have a maximum of sixty (60) days from the time of execution of the Grant to relocate and meet all remaining eligibility requirements related to relocation for receiving the award funds or the Grant will be in default. The company must also submit documentation showing acknowledgement from the Federal Agency regarding the move to Kentucky.

 

The Applicant must relocate to Kentucky before commencing work on the Federal SBIR/STTR Award. If work has commenced before the move to Kentucky, the applicant is not eligible for the Matching Funds Award Program. Also required is a certification that no less than 51% of the Applicant’s property and payroll is in Kentucky and that 51% of the Matching Funds activity will be in the state of Kentucky.

 

The Federal SBIR/STTR Program is administered by 11 Federal agencies for the purpose of providing research and development funding to small companies. Companies compete for funding under this program by submitting proposals in response to solicitations issued by participating Federal agencies. The Federal SBIR/STTR Program provides for funding competitions in two phases that are relevant to the Kentucky program: Phase I - to conduct feasibility research; and Phase II - to expand and develop Phase I results and develop commercially viable innovations. The Federal SBIR/STTR Program also includes Phase III for commercializing the product or process developed in Phase II using non SBIR/STTR funds. More information about the Federal SBIR/STTR Program may be found at: www.sbirworld.com.

 

12Exhibit 10.24

 

Notice of Award

 

	

    	
RESEARCH PROJECT
    	
Issue Date:05/09/2012
    	

    
	
Department of Health and Human Services   National Institutes of Health NATIONAL INSTITUTE ON DRUG ABUSE
    

 

THIS AWARD IS ISSUED UNDER THE AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009 AND IS SUBJECT TO SPECIAL HHS TERMS AND CONDITIONS AS REFERENCED IN SECTION III

 

Grant Number: 5RC2DA028984-02 REVISED

 

Principal Investigator(s):

AUDRA L STINCHCOMB (contact), PHD

Lynn Webster, MD

 

Project Title: Transdermal Cannabinoid Prodrug Treatment for Cannabis Withdrawal and Dependence

 

Dr. Stinchcomb, Audra , PhD 
 Chief Scientific Officer
 2277 Thunderstick Drive 
 Lexington, KY 40505

 

Award e-mailed to: astin2@email.uky.edu

 

Budget Period: 09/01/2010 - 08/31/2013 
  Project Period: 09/30/2009 - 08/31/2013

 

Dear Business Official:

 

The National Institutes of Health hereby revises this award (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to ALLTRANZ, INC. in support of the above referenced project.  This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

 

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

 

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number RC2DA028984.  The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

 

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with 42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August 24, 2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with the 1995 regulation.  The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module.  The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards.  Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

 

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

 

1

 

Sincerely yours,

 

 

Diana Haikalis
 Grants Management Officer
 NATIONAL INSTITUTE ON DRUG ABUSE

 

Additional information follows

 

2

 

SECTION I - AWARD DATA - 5RC2DA028984-02 REVISED

 

	
Award Calculation (U.S. Dollars)
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Federal   Direct Costs
    	
 
    	
$
    	
1,753,239
    	
 
    
	
Federal   F&A Costs
    	
 
    	
$
    	
179,280
    	
 
    
	
Approved   Budget
    	
 
    	
$
    	
1,932,519
    	
 
    
	
Federal   Share
    	
 
    	
1,932,519
    	
 
    
	
TOTAL   FEDERAL AWARD AMOUNT
    	
 
    	
$
    	
1,932,519
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
AMOUNT   OF THIS ACTION (FEDERAL SHARE)
    	
 
    	
$
    	
0
    	
 
    

 

SUMMARY TOTALS FOR ALL YEARS

 

	
YR
    	
 
    	
THIS AWARD
    	
 
    	
CUMULATIVE TOTALS
    	
 
    
	
2
    	
 
    	
$
    	
1,932,519
    	
 
    	
$
    	
1,932,519
    	
 
    
								

 

	
Fiscal Information:
    	
 
    	
 
    
	
CFDA   Number:
    	
 
    	
93,701
    
	
EIN:
    	
 
    	
1260389433A1
    
	
Document   Number:
    	
 
    	
RDA028984Z
    
	
Fiscal   Year:
    	
 
    	
2010
    

 

	
IC
    	
 
    	
CAN
    	
 
    	
2010
    	
 
    
	
DA
    	
 
    	
8484901
    	
 
    	
$
    	
1,932,519
    	
 
    
							

 

NIH Administrative Data:

PCC: MF/MKP / OC: 414E / Processed: HAIKALIS 05/08/2012

 

SECTION II - PAYMENT/HOTLINE INFORMATION - 5RC2DA028984-02 REVISED

 

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

 

SECTION III - TERMS AND CONDITIONS - 5RC2DA028984-02 REVISED

 

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

 

a.                                      The grant program legislation and program regulation cited in this Notice of Award.

b.                                      Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.

c.                                       45 CFR Part 74 or 45 CFR Part 92 as applicable.

d.                                      The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.

e.                                       This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

 

(See NIH Home Page at ‘http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

 

3

 

ARRA TERM OF AWARD: This award is subject to the HHS-Approved Standard Terms and Conditions for the American Recovery and Reinvestment Act of 2009.  Approved text for NIH awards can be found at http://grants.nih. gov/grants/policy/NIH_HHS_ARRA_Award_Terms.pdf.  Recipients should pay particular attention to the special quarterly reporting requirements required by Section 1512 of the Recovery Act as specified in Term #2.

 

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

 

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory.  For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov/.

 

This award provides support for one or more clinical trials.  By law (Title VIII, Section 801 of Public Law 110-85), the “responsible party” must register “applicable clinical trials” on the ClinicalTrials.gov Protocol Registration System Information Website.  NIH encourages registration of all trials whether required under the law or not.  For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/

 

This award represents the final year of the competitive segment for this grant.  Therefore, see the NIH Grants Policy Statement Section 8.6 Closeout for closeout requirements at: http://grants.nih.gov/grants/policy/#gps .

 

A final Federal Financial Report (FFR) (SF 425) must be submitted through the eRA Commons (Commons) within 90 days of the expiration date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, http://grants.nih.gov/grants/policy/#gps, for additional information on this submission requirement.  The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations.  There must be no discrepancies between the final FFR expenditure data and the Payment Management System’s (PMS) cash transaction data.

 

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted through the eRA Commons (Commons) within 90 days of the expiration date.

 

Furthermore, unless an application for competitive renewal is submitted, a final progress report must also be submitted within 90 days of the expiration date.  Institute/Centers may accept the progress report contained in competitive renewal (type 2) in lieu of a separate final progress report.  Contact the awarding IC for IC-specific policy regarding acceptance of a progress report contained in a competitive renewal application in lieu of a separate final progress report.

 

NIH strongly encourages electronic submission of the final progress report and the final invention statement through the Closeout feature in the Commons.  If the final progress report and final invention statement are not submitted through the Commons, a copy can be emailed or sent to the contacts listed below.  Copies of the HHS 568 form may be downloaded at: http://grants.nih.gov/grants/forms.htm.

 

Submissions of the final progress report and HHS 568 may be e-mailed as PDF attachments to the NIH Central Closeout Center at: DeasCentralized@od.nih.gov.

 

Paper submissions of the final progress report and the HHS 568 may be faxed to the NIH Central Closeout Center at 301 -480-2304 or mailed to the NIH Central Closeout Center at the following address:

 

NIH/OD/OER/DEAS
 Central Closeout Center
 6705 Rockledge Drive, Room 2207
 Bethesda, MD 20892-7987 (for regular or U.S.  Postal Service Express mail)
 Bethesda, MD 20817 (for other courier/express mail delivery only)

 

The final progress report should include, at a minimum, a summary of progress toward the achievement of the originally stated aims, a list of significant results (positive and/or negative), a list of publications and the grant

 

4

 

number.  If human subjects were included in the research, the final progress report should also address the following:

 

Report on the inclusion of gender and minority study subjects (using the gender and minority Inclusion Enrollment Form as provided in the PHS 2590 and available at http://grants.nih.gov/grants/forms.htm).

 

Where appropriate, indicate whether children were involved in the study or how the study was relevant for conditions affecting children (see NIH Grants Policy Statement Section 4.1.15.7 Inclusion of Children as Subjects in Clinical Research at URL http://grants.nih.gov/grants/policy/#gps).

 

Describe any data, research materials (such as cell lines, DNA probes, animal models), protocols, software, or other information resulting from the research that is available to be shared with other investigators and how it may be accessed.

 

Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the final progress report.

 

Note, if this is the final year of a competitive segment due to the transfer of the grant to another institution, then not all the requirements stated above are applicable.  Specifically a Final Progress Report is not required.  However, a final FFR is required and should be submitted electronically as noted above.  In addition, if not already submitted, the Final Invention Statement is required and should be sent directly the assigned Grants Management Specialist.

 

Treatment of Program Income:

Additional Costs

 

SECTION IV - DA Special Terms and Conditions - 5RC2DA028984-02 REVISED

 

REVISED AWARD: The purpose of this revision is to change the budget and project period end-dates from 08/31/2012 to 08/31/2013 in accordance with the letter of 05/07/12 from Audra Stinchcomb, Ph.D., C.S.O./AllTranz.

 

The National Institute on Drug Abuse (NIDA) encourages data harmonization to increase comparability, collaboration, and scientific yield of research on drug abuse.  Towards that end, NIDA strongly encourages human-subject studies to incorporate a series of measures from the Substance Abuse and Addiction Core and Specialty collections, which are available in the PhenX Toolkit (www.phenxtoolkit.org).  For more information about NIDA’s data harmonization efforts, please see NOT-DA-12-008 at http://grants.nih.gov/grants/guide/notice-files/NOT-DA-12-008.html.

 

This revision supersedes the NoA issued 06/09/11.

 

VISED:  This award is revised to lift the restriction on the obligation of funds, per the date of the Animal Subject assurances.  The human subjects restriction remains in place.  Supersedes Notice of Award dated 9/17/2010.

 

*************************

 

This revised award reflects the Office of Laboratory Animal Welfare’s (OLAW) approval of Inter-institutional Assurance’s between AllTranz, Inc. and BioReliance, Sinclair, and MPI Research, in accordance with the PHS Policy on Humane Care and Use of Laboratory Animals and removes the special condition on the award issued on 9/30/2009.  Accordingly, the special condition prohibiting research involving animal subjects is removed, effective as of the date of Inter-Institutional assurance; BioReliance Corporation (11/18/2009) , Sinclair Research Center, Inc., (11/18/2009) and MPI Research (8/30/2010).

 

****************

 

5

 

RESTRICTION: This award is issued without a Federalwide Assurance of Protection for Human Subjects for the grantee institution.  Information on and instructions for submitting and negotiating a Federalwide Assurance are available at the OHRP website http://www.hhs.gov/ohrp/.  The grantee institution must provide the National Institute on Drug Abuse (NIDA) with the submission date of required Assurance documents to OHRP and should submit these documents to OHRP in writing or via the OHRP.  The grantee is then responsible for notifying the National Institute on Drug Abuse when OHRP has approved the Assurance and for providing the National Institute on Drug Abuse with the OHRP Assurance number.  The present award is also being made without a currently valid certification of IRB approval for this project.

 

The grantee institution may conduct only activities that are clearly severable and independent from activities that involve human subjects until OHRP has approved an Assurance and the National Institute on Drug Abuse has received and accepted the grantee institution’s certification of IRB approval.

 

No funds may be drawn down from the payment system and no obligations may be made against Federal funds for any research involving human subjects prior to the National Institute on Drug Abuse’s notification to the grantee that the identified issues have been resolved and this restriction removed.

 

RESTRICTION: This award is issued subject to the following special condition: Only activities that do not directly involve human subjects (i.e., are clearly severable and independent from those activities that do involve human subjects) may be conducted under this award until the following issues SRG concerns have been resolved to the satisfaction of the National Institute on Drug Abuse: Dr. Stinchcomb’s response did not completely address all of the concerns) identified by the SRG.  The remaining concerns include informed consent procedures and elements of the consent process, inclusion/exclusion criteria, confidentiality and data safety/security (e.g., transmission of de-identified data from Lifetree to AllTranz), timeframes for drawing the plasma samples, details of the Data and Safety Monitoring Plan, and follow-up procedures for adverse events for the Phase I clinical trial to be conducted in Year 2 that need to be addressed before all concerns can be considered resolved.

 

*********

 

RESTRICTION: The present award is being made without a currently valid certification of Institutional Review Board (IRB) approval for this project with the following restriction: Only activities that are clearly severable and independent from activities that involve human subjects may be conducted under this award until the project has received IRB approval consistent with 45 CFR Part 46 and certification of IR approval has been submitted to and accepted by the NIH awarding component.

 

No funds may be drawn down from the payment system and no obligations may be made against Federal funds for research involving human subjects by the grantee or any other site engaged in such research for any period not covered by an OHRP-approved Assurance and IRB approval consistent with 45 CFR Part 46.

 

Failure to comply with the above requirements may result in suspension and/or termination of this award, withholding of support, audit disallowances, and/or other appropriate action.

 

See the NIH Grants Policy Statement, December 2003,(http://grants2.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part5.htm), pages 54-56 for specific requirements related to the protection of human subjects, which are applicable to and a term and condition of this award.

 

****************

 

This award includes funds awarded for consortium activity with Life Tree Clinical Research, MPI Research, BioReliance, Xenometrics and Sinclair.  Consortiums are to be established and administered as described in the NIH Grants Policy Statement (NIH GPS).  The referenced section of the NIH Grants Policy Statement is available at http://grants1 .nih.gov/grants/policy/nihgps_2003/NIHGPS_Part12.htm#_Toc54600251, pages 224-227.

 

*******

 

6

 

The following principal investigators (PIs) are associated with this project: Audra Stinchcomb, Ph.D., Chief Scientific Officer and Founder of AllTranz, Inc. and Lynn Webster, MD, PI, Life Tree Clinical Research .  Dr. Stinchcomb is the contact PI for correspondence purposes.

 

Prior Approvals: Consistent with NOT-OD-06-054, (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-054.html), as this grant has multiple Principal Investigators (PIs), although the signatures of the PIs are not required on prior approval requests submitted to the agency, the grantee institution must secure and retain the signatures of all of the PIs within their own internal processes.

 

*******

 

None of the funds in this award shall be used to pay the salary of an individual at a rate in excess of the current salary cap.  Therefore, this award and/or future years are adjusted accordingly, if applicable.  Current salary cap levels can be found at the following: http://grants2.nih.gov/grants/policy/salcap_summary.htm

 

All grantees must acknowledge funding received from the National Institute on Drug Abuse at the National Institutes of Health when issuing statements, press releases, requests for proposals, bid solicitations, and other documents describing projects or programs funded in whole or in part with NIDA money. (NIH Grants Policy Statement, Part II, Page 114- Rights in Data (Publication and Copyrighting), December 2003).

 

In conjunction with this requirement, in order to most effectively disseminate research results, advance notice should be given to NIDA that research finds are about to be published so that we may coordinate accurate and timely release to the media.  This information will be embargoed until the publication date.  Any press notification should be coordinated with the NIDA Press Officer who can be reached at (301) 443-6245.

 

We strongly encourage all of our grantees to register in the eRA Commons.  The eRA Commons provides grantees with the ability to electronically submit; e-SNAP applications, No cost extensions, Just in Time documents, Financial Status Reports, Final Progress Reports, and allows grantees to register to become e-mail enabled to receive Notice of Grant Awards (NGA).

 

NIDA has an interest in supporting HIV/AIDS and infectious disease research.  The purpose of this support is to develop effective prevention, treatment, and service strategies for drug abusing youth and adults.  To that end, awardees conducting HIV/AIDS research are encouraged to make every effort to incorporate scientific questions related to HIV/AIDS and other infectious diseases into research protocols.  Principal Investigators will be required to provide information related to the development of research in this area in annual progress reports to allow NIDA to assess progress regarding HIV/AIDS research.

 

STAFF CONTACTS

 

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions.  The Program Official is responsible for the scientific, programmatic and technical aspects of this project.  These individuals work together in overall project administration.  Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist.  Requests may be made via e-mail.

 

Grants Management Specialist: Diana Haikalis

Email: dh84m@nih.gov Phone: (301) 435-1373 Fax: (301) 594-6849

 

Program Official: Moo Kwang Park

Email: MP264A@NIH.GOV Phone: (301) 443-9813

 

SPREADSHEET SUMMARY

GRANT NUMBER: 5RC2DA028984-02 REVISED

 

INSTITUTION: ALLTRANZ, INC.

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]